July 16, 2020
NIH, Moderna’s COVID-19 vaccine headed to Phase III trial
Editor's Note
Researchers testing a COVID-19 vaccine being developed by Dr Anthony Fauci’s team at the National Institutes of Health (NIH) and Moderna Inc, reported July 14 that the vaccine was able to produce neutralizing antibodies in the 45 trial participants inoculated in March.
Moderna is scheduled to launch a late-stage trial to evaluate the vaccine in 30,000 volunteers at the end of July.
Free Daily News
- Back to Business: Budgeting for Sustainable Staffing Models in the OR
- Healthcare job gain in August offset by losses in federal government, other industries
- AHA study: HOPD Medicare patients are poorer, sicker, more rural than those seen in physician offices
- ACS, Lifesaving Technologies launch nationwide effort to expand bleeding control readiness
- Minimally invasive ICH surgery evacuates clot fast but fails to improve 6-month outcomes
- Rural hospitals face crisis under OBBBA as experts call for cohesive reform
- AMA urges health systems to act now on AI governance
- Suicide Prevention Month: Hospitals prepare for new The Joint Commission suicide prevention goal, effective 2026
- Survey: Perioperative leaders adapt to supply strain, staffing pressure, ASC growth
- Gait retraining eases knee osteoarthritis pain as effectively as medication, can delay knee surgery
© Access Intelligence, LLC. All rights reserved. |
Privacy Policy |
Cookie Settings |
Diversity, Equity, Inclusion & Belonging |
Accessibility Statement